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OBJECTIVES: The removal of pre-malignant colorectal lesions prevents cancer. Hyoscine has been proposed as a
means of improving diagnosis by reducing colonic movements. The aim of this study was to analyze whether
this anti-spasmodic enhances the detection of pre-malignant colorectal lesions.
METHODS: In a randomized, double-blinded fashion patients received hyoscine or a saline solution in all
consecutive colonoscopies in which the cecum was reached. Lesions were analysed with respect to number, size,
location, histology and capillary pattern.
RESULTS: A total of 440 colonoscopies were randomized. The overall polyp detection rate (PDR) and the
adenoma detection rate (ADR) were 65.2% and 49.3%, respectively. In the hyoscine group, non-polypoid
lesions were detected significantly more often (p=0.01). In the placebo group 281 lesions were diagnosed
(202 adenomas) and in the hyoscine group 282 lesions were detected (189 adenomas) (p=0.23). The PDR and
ADR were similar between the placebo and hyoscine groups (64% vs 66% and 50% vs 47%, respectively).
No differences were observed between the two groups in the advanced-ADR or advanced neoplasia detection
rate, as well the mean numbers of polyps, adenomas, advanced adenomas and advanced neoplasias detected
per patient. The administration of hyoscine also did not improve the diagnostic accuracy of digital chromo-
endoscopy. The presence of adenomatous polyps in the right colon was detected significantly more frequently
in the hyoscine group (OR 5.41 95% CI 2.7 - 11; po0.01 vs OR 2.3 95% CI 1.1 - 4.6; p=0.02).
CONCLUSION: The use of hyoscine before beginning the withdrawal of the colonoscope does not seem to
enhance the PDR and the ADR.
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’ INTRODUCTION
Colorectal cancer (CRC) represents one of the leading causes
of cancer-related deaths worldwide. The diagnosis of pre-
malignant lesions, and the subsequent removal of such
lesions is a well-recognized strategy in the secondary pre-
vention of CRC (1). Colonoscopy is considered the gold
standard in achieving this goal, with the adenoma detec-
tion rate (ADR) (defined as the index of procedures in which
at least one adenoma is diagnosed) considered a known indicator
of the quality of the method (2). Nevertheless, a considerable
number of adenomas are missed (3,4), which are related to
interval cancer, especially in the right colon (5). Interval cancer
in the right colon could be partially explained by the non-
diagnosis of non-polypoid lesions, since these neoplasms are
more common in the right colon and are more aggressive (6).
Many factors could contribute to the failure to diagnose
these lesions, including inadequate bowel preparation (7,8),
colonoscopy technique (9), colonoscope withdrawal time (10)
and polyp location (11,12). New techniques have been developed
to increase the ADR, such as high-definition colonoscopes (13),
chromoendoscopy (14), G-EYE colonoscope (15), the Third
Eye colonoscope (16), full spectrum endoscopy (17), water-
immersion colonoscopy (18), retroflexion in the right colon (19),
cap-assisted colonoscopy (20), endocuff-assisted colono-
scopy (21), and endorings (22).
It has been suggested that colonic peristalsis may hinder
the analysis of the mucosal surface, and consequently the
discovery of colonic lesions.
Hyoscine is a spasmolitic agent of the gastrointestinal tract.
The peripheral anticholinergic action of hyoscine results from
the blockade of the intramural ganglia of hollow viscera, asDOI: 10.6061/clinics/2017(07)01
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well as an anti-muscarinic activity. The antiperistaltic effect
of this compound on the small intestine was demonstrated
by Gutzeitet et al. (23), with an average onset of action
at 85 seconds after intravenous infusion and an average
duration of 21 minutes. The administration of hyoscine
during colonoscopy could be an alternative in controlling
colonic contractility and could in this way facilitate the
detection and characterization of colonic lesions. However,
anti-spasmodic agents such as glucagon (24) and atropine (25)
have not shown benefits in this setting. Hyoscine is inex-
pensive, widely available and safe. Furthermore, there
have been no studies to date evaluating the use of spas-
molytic agents in the differential diagnosis of colorectal
lesions by digital chromoendoscopy. It was hypothesized
that the analysis of the capillary pattern of colorectal lesions
would be facilitated under the effect of hyoscine, which
decreases the peristaltic movements of the colon.
The goal of this prospective, randomized, placebo-
controlled double-blinded trial was to analyse whether
the use of hyoscine enhances the detection of polyps and
adenomas. As a secondary objective, this study aimed to
evaluate whether this drug has any impact on the dif-
ferential diagnosis of colorectal lesions during colonoscopy
with magnification and digital chromoscopy.
’ METHODS
The participating institutions were as follows: Santa
Casa de Caridade de Bagé, RS; Evangelic Faculty of Parana,
Curitiba, PR; and Santa Casa Hospital, Porto Alegre, RS.
The study was approved by the Ethics Committee of Santa
Casa de Caridade, Bagé, RS and was conducted according
to the Declaration of Helsinki. Informed written consent
(26) was obtained from all participants.
Patients who were referred to our endoscopy unit for
CRC screening, surveillance or a clinical suspicion of CRC
were randomly assigned to receive 20mg of hyoscine (Buscopan,
Boehringer Ingelheim of Brazil Quim. e Farm. Ltda,
Itapecerica da Serra, Brazil) or placebo (saline solution) as
soon as the colonoscope reached the cecum. The randomi-
zation was generated by the www.researchrandomizer.org
site. Sealed envelopes were opened by the nurse taking care
of the patient’s sedation. The endoscopist was blinded to
the randomization. The exclusion criteria were as follows:
inadequate bowel preparation, incomplete colonoscopy,
inflammatory bowel disease, advanced cancer, prior color-
ectal surgery, reported or known allergy to hyoscine, and
patients referred to polypectomy or endoscopic mucosal
resection due to previously diagnosed lesions.
Between March and July 2015, 517 consecutively performed
colonoscopies were analysed for inclusion in the study. A total
of 77 cases were excluded: 20 had previously diagnosed colon
lesions and were referred for colonoscopic removal; 13 had
previously undergone colon resection surgery; 11 had inade-
quate bowel preparation; 7 had advanced carcinomas; 7 were
aged less than 30 years; 7 being allergic to hyoscine and in
2 cases the cecum was not reached. Therefore, 440 cases were
randomized, with 220 cases in each arm. The patients were
analysed with respect to age, gender, colonoscope withdrawal
time, endoscopic findings and histopathology.
Procedures
Bowel preparation was undergone with a clear liquids diet
on the day prior to the procedure and 1000 ml of a 10%
mannitol solution on the day of lower endoscopy. All colo-
noscopies were performed under conscious sedation with
midazolamand fentanyl.
One millilitre of hyoscine (20 mg) or placebo was infused
intravenously as soon as the cecum was reached during
colonoscopy (Fujinon 590ZW5 with high resolution and
magnification, Fujifilm Corp., Saitama, Japan) with the
EPX4400 processor. We waited for at least one minute before
starting withdrawal, of the coloscope because the antispasmodic
effect begins within one minute and lasts for 10-15 minutes (27).
All procedures were performed by one of the authors (CEOS)
who had already performed more than 12,000 colonoscopies
with magnification and real or digital chromoendoscopy.
The colonoscope withdrawal time was defined as the time
spent between cecum examination after the intravenous
administration of the drug or placebo and the removal of the
colonoscope through the anus. In all cases, this procedure
lasted more than 6 minutes.
Patients were monitored continuously during the exam-
ination by means of a pulse oximeter. The alarm remained off
during the colonoscopies and the monitor was seen only by
the nurse and not by the endoscopist. To maintain patient
safety, the nurse was instructed to communicate with the
endoscopist in case of significant tachycardia, which was
considered relevant when the heart beat rate was greater
than 140/minute for more than 30 seconds (28).
Lesions characteristics
The lesion size was estimated with an open biopsy forceps
(7mm). The lesions morphology was determined according
to the Paris classification (29), in which non-polypoid lesions
are considered those less than 2.5mm in height, which was
estimated with a closed biopsy forceps touching the lateral
margins of the lesion, (types 0-IIa, 0-IIa+IIc, 0-IIc+IIa, 0-IIc,
and 0-IIb and laterally spreading tumors - LSTs). Polypoid
lesions are those greater than 2.5mm in height (types 0-Is,
0-Isp, and 0-Ip). All lesions included in the study had the
endoscopic appearance of lesions known as superficial lesions,
limited to the mucosa or submucosa, according to Kudo (30).
The right colon was considered the cecum, and the ascend-
ing and transverse colon, while the left colon was the rectum,
the sigmoid and the descending colon.
All lesions were evaluated using digital chromoendoscopy
(Flexible Spectral Imaging Color Enhancement – FICE) to
analyse capillary patterns for the real time differential
diagnosis between neoplastic and non-neoplastic lesions.
According to the Teixeira Classification (31), lesions with
I-II patterns were considered non-neoplastic, and lesions with
III-V patterns were considered neoplastic. Non-neoplastic
lesions were hyperplastic and inflammatory polyps, and
neoplastic lesions were tubular, tubulovillous, villous, sessile
serrated, and traditional serrated adenomas and early car-
cinomas. Those lesions greater than 1 cm, with villous
histology or high-grade dysplasia were considered advanced
adenomas. Advanced neoplasias were the advanced adeno-
mas and early carcinomas.
All the lesions were removed endoscopically and were
analysed by the same pathologist who was blinded to the
endoscopic diagnosis.
Statistical Analysis
The data were inserted into the Stata software version 11.2.
Categorical variables were described using absolute and
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relative frequencies. Numerical variables were described as
the mean and standard deviation (SD) when the distribution
of the data was normal or as the median and interquartile
interval when their distribution was not normal.
Bivariate analyses of the categorical variables comparing
the hyoscine and placebo groups were performed using
Fisher’s exact test. Bivariate analyses of numerical variables
comparing the groups with and without hyoscine were per-
formed using a t-test (when comparing means) or the Mann-
Whitney U test (when medians were compared).
A logistic regression was used to analyse the adenoma
detection rate (ADR) with the odds ratio (OR) and con-
fidence interval (95% CI). For the sample size calculation, the
analysis of the detection rate of adenomas was considered
as an outcome, stratified according to the treatment group
(hyoscine) and control group (placebo). The parameters
considered were as follows: power of 80%, alpha-error of 5%,
prevalence of 50% outcome, 10-75% exposure frequency and
relative risk of at least 1.7 or an odds ratios of 2.6 between
exposed versus unexposed, resulting in a patient number of 216.
The sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) of the capillary pattern
analysis were reported. The significance level adopted was
5% for the bicaudal tests.
’ RESULTS
From a total of 517 consecutive patients, 77 (14.9%) did
not meet the inclusion criteria. Therefore, 220 patients were
randomized to the hyoscine group, and the other 220
were included in the placebo group. A total of 563 lesions
were diagnosed in 287 colonoscopies (65.2%), with 391 adenomas
in 217 patients (49.3%). These figures are described in Table 1.
Sex, age, mean lesion size (4.9 mm+/- 4.2 vs 5.3 mm+/- 6.2,
p=0.46), and mean colonoscope withdrawal time (9.8 min
+/- 5.7 vs 9.8 min +/- 8.3, p=0.99) were similar between
the two groups. However, the median and the interquartile
interval were higher in the placebo group with respect
to the colonoscope withdrawal time [7.7 min (7.1-9.8) vs
7.5 min (6.8-8.6), p=0.05].
In the hyoscine group, significantly more non-polypoid
lesions were detected than in the placebo group (79.8% vs
69.4%); nevertheless, polypoid lesions composed 20.2% of
the lesions in the hyoscine group and 30.6% in the placebo
group (p=0.01). The proportion of adenomas and non-polypoid
adenomas found in the right colon was similar between the
two groups.
Analysing the lesions via digital chromoendoscopy in the
placebo group, the accuracy was 94.3%, the sensitivity 94.1%,
the specificity 94.7%, the PPV 98% and the NPV 85.7%, while
these values were 95%, 93.7%, 97.8%, 98.9% and 88.1%,
respectively, in the hyoscine group (Table 2, all these data
were not significantly different).
The detection of advanced adenomas (12.7% vs 11.8%) and
advanced neoplasias (13.6% vs 12.3%), the PDR (64.6% vs
65.9% ) and the ADR (50.5% vs 46.8%) were also similar
between the placebo and the hyoscine groups, respectively
(Table 1), as well as the mean number of polyps (1.3 vs 1.3),
adenomas (0.92 vs 0.86), advanced adenomas (0.16 vs 0.18) and
advanced neoplasias (0.16 vs 0.18) detected per patient (p=0.97).
The logistic regression analysis demonstrated that 1 addi-
tional minute of colonoscope withdrawal time and the
presence of one more lesion were associated with the
detection of one more adenoma in the placebo group, and
the presence of a lesion in the right colon was associated with
the detection of more lesions in the hyoscine group.
Polypoid lesions were a risk factor for adenoma only in the
placebo group. The complete logistic regression analysis is
depicted in Table 3.
No serious side effects were observed in the study groups.
Three patients presented with significant tachycardia lasting
less than 30 seconds in the hyoscine group.
’ DISCUSSION
We hypothesized that the spasmolytic action of hyoscine
would favour a greater detection of polyps and adenomas,
Table 1 - Patient and lesion characteristics.
Variable Placebo
group (%)
Hyoscine
group (%)
p value*
N=220 patients N=220 patients
Sex 0.76
Female 151 (68.6) 147 (66.8)
Male 69 (31.4) 73 (33.2)
Age (years) 0.50
o50 47 (21.4) 54 (24.6)
X50 173 (78.6) 166 (75.4)
Lesions per patient 0.65
0 78 (35.4) 75 (34.0)
1 68 (30.9) 71 (32.3)
2 38 (17.3) 42 (19.1)
3 24 (10.9) 16 (7.3)
X4 12 (5.5) 16 (7.3)
Size (mm) N= 281 lesions N=282 lesions 1.00
o10 262 (93.2) 262 (92.9)
X10 19 (6.8) 20 (7.1)
Morphology 0.01
Non-polypoid 195 (69.4) 225 (79.8)
Polypoid 86 (30.6) 57 (20.2)
Capillary pattern 0.15
Non-neoplastic 84 (29.9) 101 (35.8)
Neoplastic 197 (70.1) 181 (64.2)
Pathology 0.20
Non-neoplastic 76 (27.1) 91 (32.3)
Neoplastic 205 (72.9) 191 (67.7)
Adenomas 0.23
No 79 (28.1) 93 (33.0)
Yes 202 (71.9) 189 (67.0)
Advanced adenoma 0.62
No 247 (87.9) 243 (86.2)
Yes 34 (12.1) 39 (13.8)
Advanced neoplasia 0.71
No 245 (87.2) 242 (85.2)
Yes 36 (12.8) 40 (14.8)
Advanced histology 0.45
No 265 (94.3) 270 (95.7)
Yes 16 (5.7) 12 (4.3)
Location 0.18
Right Colon 152 (54.1) 136 (48.2)
Left Colon 129 (45.9) 146 (51.8)
Table 2 - Diagnostic criteria of the lesions using digital
chromoendoscopy.
Placebo group (n=281) Hyoscine group (n=282)
Sensitivity (%) 94.1 (90.0 - 95.9) 93.7 (89.3 - 95.7)
Specificity (%) 94.7 (87.1 - 98.5) 97.8 (92.3 - 99.7)
PPV (%) 98.0 (94.9 - 99.4) 98.9 (96.1 - 99.9)
NPV (%) 85.7 (76.4 - 92.4) 88.1 (80.2 - 93.7)
Accuracy (%) 94.3 95
Kappa 0.86 (0.79 - 0.93) 0.89 (0.83 - 0.95)
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thus increasing the ADR. Other studies have suggested
that the administration of a spasmolytic drug could also
facilitate the insertion of the colonoscope to the cecum (32,33)
or could improve the visualization of the colonic surface due
to the reduction of spasms and the flattening of the colonic
haustrations (34). However, these results were not repro-
duced by other authors (35,36).
Employing a grading scale for colonic spasms, Lee et al.
(37) observed a significant decrease in the number of spasms
between colonoscope insertion and withdrawal in patients
receiving hyoscine in comparison to those receiving placebo.
However, this group did not show any difference in the num-
ber of polyps per patient or the ADR. Nonetheless, Lee et al.
found a trend for a higher polyp detection rate in the hyo-
scine group when comparing a subgroup of placebo patients
with severe spasms. Our study did not show an advantage
to injecting hyoscine when the colonoscope reached the
cecum in terms of the PDR or ADR, which is in line with two
recently published metanalyses (38,39). There was also no
diagnostic advantage either in the detection of advanced
adenomas, or advanced neoplasias.
In a study of 601 patients, Corte et al. (40) identified
a higher polyp rate per patient in a hyoscine group than in a
placebo group (0.91 vs 0.7 p=0.04), but the PDR and ADR
were similar for both arms (43.6 vs 36.6% and 27.1% vs 21.8%,
respectively). In a study by de Brouwer et al. (41), there was
no difference in the PDR, ADR or mean number of polyps
detected per patient, in an Italian double-blind, randomized
trial comparing hyoscine and placebo (28).
The present study also did not demonstrate any difference
in the PDR, ADR, or mean number of detected polyps
or adenomas per patient when comparing hyoscine with
placebo.
In contrast to the findings of Rondonotti et al. (28), who
encountered significantly fewer non-polypoid colorectal lesions
in the hyoscine group, we found significantly more non-
polypoid colorectal lesions in the hyoscine arm. Our findings
refute the hypothesis that spasmolytic agents would hinder
the identification of flat lesions by stretching of the colon.
However, de Brouwer et al. (41) identified no difference in
the morphology of the diagnosed colorectal lesions, when
comparing hyoscine and placebo.
We observed a longer withdrawal time in the placebo
group, which in our study, was associated with the ADR
according to the logistic regression analysis. In contrast, in
the hyoscine group, the main factor associated with the ADR
was the detection of a lesion in the right colon. These figures
are comparable to those reported by Corte et al. (40). Perhaps
this longer withdrawal time in the placebo group can be
explained by waiting for the colonic spasms to end during
the examination.
The analysis of the capillary pattern by magnification
colonoscopy with digital chromoscopy has yielded excellent
results in the differential diagnosis of neoplastic and non-
neoplastic colorectal lesions, with good to excellent intra-
and interobserver agreement (42-45). We also hypothesized
that the abolishment of colonic contractility would allow a
better evaluation of these lesions by digital chromoendo-
scopy with magnification. However, no differences regarding
the diagnostic sensitivity, specificity, PPV, NPV or accuracy
were observed when comparing patients who received
placebo or hyoscine. Perhaps, the use of hyoscine could
improve the discrimination between neoplastic and non-
neoplastic colorectal lesions, and improve the PDR and ADR
among beginners, but not after the acquisition of expertise.
Indeed, one of the limitations of this study is that all the
examinations were performed by a single endoscopist, who
is very familiar with the Japanese Classification of Colorectal
Carcinoma (46), which may explain the large number of
lesions morphologically classified as NPLs.
In summary, we found a higher number of non-polypoid
lesions in the hyoscine group and more polypoid lesions in
the placebo group, but with no difference with respect to the
colonic segment (left or right). This double-blind, prospec-
tive, placebo-controlled trial did not show any evidence
supporting the routine use of hyoscine during colonoscopy
to improve the PDR and ADR or to augment the diagnosis of
advanced adenomas or advanced neoplasias. We could also
not demonstrate an impact of the drug in differentiating
neoplastic from non-neoplastic lesions by means of digital
chromoendoscopy with magnification.
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